The current integrative pathobiologic hypothesis states that pancreatic cancer (PDAC) develops and progresses in response to an interaction between known oncogenes and downstream epigenomic regulators. Congruently, this study tests a new combinatorial therapy based on the inhibition of the Aurora kinase A (AURKA) oncogene and one of its targets, the H3K9 methylationbased epigenetic pathway. This therapeutic combination is effective at inhibiting the in vitro growth of PDAC cells both, in monolayer culture systems, and in three-dimensional spheroids and organoids. The combination also reduces the growth of PDAC xenografts in vivo. Mechanistically, it was found that inhibiting methyltransferases of the H3K9 pathway in cells, which are arrested in G 2 -M after targeting AURKA, decreases H3K9 methylation at centromeres, induces mitotic aberrations, triggers an aberrant mitotic check point response, and ultimately leads to mitotic catastrophe. Combined, these data describe for the first time a hypothesis-driven design of an efficient combinatorial treatment that targets a dual oncogenic-epigenomic pathway to inhibit PDAC cell growth via a cytotoxic mechanism that involves perturbation of normal mitotic progression to end in mitotic catastrophe. Therefore, this new knowledge has significant mechanistic value as it relates to the development of new therapies as well as biomedical relevance.
Introduction
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States, with a median survival of 6 months (1). PDAC presents with aggressive biology, rapid dissemination, and late diagnosis, leading to an incurable stage for which therapy is a challenge. Surgery remains the only curative modality, but is only applicable to 10% of patients, with 5-year survival barely 20% (2) . Notably, PDAC is highly resistant to chemoradiation (3) . Thus, there remains a crucial need for the development and evaluation of novel targeted therapies.
Current evidence suggests that PDAC results from a crosstalk between oncogenes and epigenetic regulators, which together are responsible of the malignant phenotype. Thus, combinatorial therapies targeting both components may provide a useful approach to ameliorate PDAC initiation and progression. Regarding pharmacologically targetable oncogenes, recent studies have examined the effects of inhibiting Aurora kinase A (AURKA) in PDAC (4, 5) . AURKA is a G 2 -M kinase that plays crucial roles in cell division (6) . AURKA expression is aberrant in many malignancies, including PDAC (7) . Altered AURKA activity contributes to tumor progression by inducing abnormal G 2 -M transition, centrosome amplification, and chromosome instability (8) . Both genetic and pharmaceutical AURKA inhibition has cytostatic effects through G 2 -M arrest (9, 10) and senescence (10) . As these combined cellular effects lead to growth inhibition in PDAC cells and xenografts (9) , AURKA has become a molecular target for PDAC treatment. MLN8237 (alisertib) selectively inhibits AURKA (11) and is currently under phase I and II clinical trials for solid tumors and hematologic malignancies. However, its underlying mechanisms are not fully understood deserving further investigations into combinatorial therapies that may improve its effects.
Interestingly, AURKA phosphorylates proteins associated with mitotic regulation through spatially and temporally controlled mechanisms (6) , which include epigenetic regulators. We have shown that a member of the methyl lysine 9 histone 3 (H3K9me) pathway, HP1g (CBX3), is phosphorylated by AURKA to support normal mitotic progression (12) . The K9H3me histone mark to which HP1 binds is established by the H3K9 histone methyltransferases (HMT) G9a, GLP, SUV39H1, and SUV39H2. HP1, in conjunction with these proteins, forms a multimeric complex that, in a timely manner, deposits and reads the H3K9me mark, genome-wide. Here, we investigate the effect of targeting both the AURKA and H3K9me pathways on PDAC growth. We find that the treatment of PDAC cells with individual drugs against AURKA or H3K9me HMTs inhibits cell growth. However, the combination of these agents has an improved effect of reducing cell growth through a cytotoxic effect. Enhanced inhibition of cell growth with the combination is also observed in spheroid and organoid models. In vivo treatment of PDAC orthotopic xenografts with the H3K9me HMT inhibitor alone reduces PDAC growth, and increased efficacy in PDAC growth reduction is observed in combination with the AURKA inhibitor over individual treatments. Confocal and electron microscopy, along with cell-cycle analysis, demonstrate that the cytotoxic effect of this combination is due to the induction of mitotic cell death. The cellular response to combined treatment was also observed at the RNA-seq level, reflected by expression changes of genes involved in drug metabolism, mitotic chromosome-associated noncoding regulatory RNAs (mCAR), and genes associated with chromosome structure. Moreover, we observed a dramatic reduction in centromeric H3K9 methylation in combination compared with individual inhibitors. Biochemical alterations of centromeres are known to activate cell-cycle checkpoints and induce chromosomal instability (13) . Congruently, at the molecular level, we find that while AURKA inhibition alone triggers a Chk1-Cdc25c-Cdk1-dependent G 2 -M arrest, the combination with H3K9me HMT inhibition regulates checkpoint proteins in a manner that allows the bypass of this G 2 -M arrest with downregulation of Chk1-p53 pathway to ultimately culminate in mitotic catastrophe. Therefore, our data demonstrate that combined targeting of AURKA and the epigenetic H3K9me HMT pathway decreases cytostatic effects to increase their cytotoxicity. Furthermore, our experiments unravel cellular and molecular mechanisms on how this combinatorial therapy works to bring about mitotic catastrophe, which is a desirable therapeutic outcome.
Materials and Methods

Cell lines and reagents
Human PDAC cell lines were obtained from the ATCC and maintained according to their recommendations. L3.6, originally isolated by Bruns and colleagues (14) , was cultured in appropriate media. The mouse PDAC cell line Pan02, syngeneic to C57BL/6, was obtained from DTP, DCTD Tumor Repository (National Cancer Institute, Bethesda, MD) and maintained according to the manufacturer's recommendations. All cell lines were cultured at 37 C in a humidified incubator supplemented with 5% CO 2 and passaged a maximum of 30 times prior to restarting cultures from cryogenically preserved stocks. Cell lines tested negative for mycoplasma within the last 6 months, and due to low passage, were not authenticated by our laboratory. For orthotopic tumors, Pan02 cells were incubated for 72 hours with lentivirus to induce stable expression of luciferase. For in vitro studies, compounds were dissolved in DMSO and stored as 100 mmol/L aliquots at
À80
C (MLN8237, Selleck Chemicals, ApexBio) or À20 C (Chaetocin, Sigma-Aldrich).
Cell growth and synergy assays
Cell lines were treated with various concentrations of MLN8237 or chaetocin, as indicated. Relative cell viability was determined by colorimetric MTS assay (CellTiter 96 AQueous One Solution Cell Proliferation Assay, Promega) according to the manufacturer's suggestions. For drug combinations, cells were treated with eight independent concentrations at a fixed ratio (1:2) or five independent concentrations at fixed ratios (1:3 or 1:5) of chaetocin:MLN8237. The fraction affected (Fa) was calculated on the basis of MTS measurements of treated samples normalized to untreated controls and the maximum biological effect of each cell line. A combination index (CI) was calculated by the median-drug effect analysis method developed by Chou and Talalay (15) using the CompuSyn software (ComboSyn, Inc), where CI < 1, 1, or > 1 indicates synergistic, additive, and antagonistic effect, respectively.
Clonogenic assays
PDAC cells were plated on 60-mm dishes at 10% confluence (1.5 Â 10 4 ). After drug exposure, cells were fixed for 10 minutes with 10% methanol/10% acetic acid and subsequently stained with 0.1% crystal violet (Sigma-Aldrich). Cell density was quantified by ImageJ (16) .
Spheroid and organoid assays
PANC-1 cells were allowed to form spheroids in a threedimensional (3D) methylcellulose matrix (17) . After 4 days, media were replaced and drugs added. After 72 hours of treatment, viability was measured by APH assay (17) on the Bio-Rad iMark Microplate reader at 415 nm. Organoid cultures were established following previously published protocol (18) . Briefly, male Ela-Kras mice (19) were euthanized, pancreas aseptically removed, digested, and ducts were isolated and grown in Matrigel (Corning) domes. One day prior to treatment, organoids were split into 96-well plates with Matrigel. Viability was assessed with the CellTiter-Glo 3D assay (G9682, Promega) on the Promega's GloMax. Bright-field images were captured by a Canon EOS Rebel Xsi camera mounted on a Nikon Eclipse TS100 microscope at 10Â magnification.
Orthotopic xenografts
Animal experiments were reviewed by Mayo Clinic and followed the guidelines outlined in the Guide for Care and Use of Laboratory Animals (NIH) under IACUC-approved protocol (A24815-15). C57Bl/6 mice (The Jackson Laboratory, aged 6-8 weeks) were anesthetized, subjected to a small incision to expose the tail of the pancreas, and injected with 5 Â 10 5 Pan02 þ luciferase cells in 25% Matrigel (BD Biosciences). Mice were observed daily and recovered 1 week before treatment initiation. MLN8237 was resuspended in 10% 2-hydroxypropylb-cyclodextrin (2OHpbCD; Sigma-Aldrich)/1% sodium bicarbonate solution at 3 mg/mL. Chaetocin was resuspended at 1 mmol/L in DMSO and diluted to 100 mmol/L in saline. Mice were randomly divided into four groups and treated daily with vehicle, MLN8237 (30 mg/kg, gavage), chaetocin (0.279 mg/kg, intraperiotenally), or combination (n ¼ 5/group). For tumor monitoring, mice were anesthetized with 0.5% inhaled isoflourane, injected with D-luciferin (112.5 mg/kg), and total flux (p/s) was quantified by Xenogen's IVIS-200 luminescence imaging system. Animals were euthanized after 10 treatments and pancreatic tissues were formalin-fixed and paraffin-embedded for histology.
Cell viability, apoptosis, and cell-cycle FACS analysis
Cells were plated at 5 Â 10 3 cells/well, treated, and cell viability and apoptosis were measured with the ApoTox-Glo Triplex Assay (G6321, Promega) on Promega's GloMax at indicated times. For FACS, cells were prepared as described previously (20) . DNA content was analyzed on a Becton Dickinson LSR II FACS instrument at the Mayo Flow Cytometry Core Facility. Events (2-4 Â 10 4 ) were collected and analyzed with appropriate gating in FlowJo software (FlowJo).
Immunofluorescence and confocal microscopy
Immunofluorescence and confocal microscopy were performed as described previously (21) . For mitotic aberrations, cells were stained with a/g-tubulin primary antibodies (Supplementary Table S1 ) and counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI) mounting media (Vector Laboratories). Images were obtained on a Zeiss AxioObserver LSM780 with objective alpha plan-apochromat 100Â/1.46 oil iris.
Electron microscopy
PANC-1 cells were treated and harvested for fixation in Trump solution (4% formaldehyde þ 1% glutaraldehyde in 0.1 mol/L phosphate buffer) overnight at room temperature. Subsequently, cells were fixed in 1% osmium tetroxide and 1% aqueous uranyl acetate, dehydrated in a graded series of ethanol, and embedded in Embed 812/Araldite (EMS). Thin sections (0.1 mm) were collected on copper grids and poststained with lead citrate. Images were acquired in the Mayo Clinic Microscopy and Cell Analysis Core facility using a JEOL1400 TEM operating at 80 kV (Jeol USA, Inc) equipped with a Gatan Orius832 camera (Gatan Inc.).
IHC
IHC was performed on pancreatic tissue as described previously (22) . Slides were incubated overnight with primary antibody (Supplementary Table S1 ) and developed with Nova Red (Vector Laboratories) and hematoxylin counterstain. Five random fields (40Â NA 0.65 A-Plan objective using Mikroscan D2 Digital Slide Scanner with Q-Skan) per pancreas were imaged and counted (23) . Each field contained at least 1,000 cells.
RNA-sequencing and real-time qPCR
RNA was isolated using RNeasy mini kit with optional oncolumn DNA digestion (Qiagen). Libraries were prepared (Illumina TruSeq mRNA v2) and run on the Illumina High Seq-2000 (101-bp paired end reads) in the Mayo Clinic Sequencing Core. RNA-Seq data were analyzed using MAP-RSeq v.1.2.1 (24) . MAPRSeq consists of alignment with TopHat 2.0.6 (25) against the hg19 genome build and gene counts with the HTSeq software 0.5.3p9 (http://htseq.readthedocs.io/en/release_0.9.1/) using gene annotation files obtained from Illumina (http://cole-trap nell-lab.github.io/cufflinks/announcements/igenomes-released/). Principal component analysis and unsupervised hierarchical clustering were performed on the samples using Partek Genomics Suite software (version 6.6; 2016, Partek Inc.). Normalization and differential expression analysis were performed using edgeR2.6.2 (26) . Data are available through the GEO repository under accession number GSE97215. Real-time qPCR was performed using RT 2 SYBR Green qPCR Mastermix (Qiagen) and RT 2 qPCR Primers (Qiagen) on the Bio-Rad CFX96 system. Fold changes (DDC t ) and P values were calculated using Bio-Rad CFX manager and SABioscience's RT 2 Profiler PCR Array Data Analysis software. Treatment samples were compared with vehicle and normalized to a panel of housekeeping genes.
Western blot analysis
Western blots were performed as described previously (12) . Membranes were blocked in 3% BSA/TBST and incubated overnight at 4 C with primary antibody (Supplementary Table S1 ). Blots were developed by Pierce ECL Chemiluminescence Substrate (Thermo Scientific).
Results
Similar to the Aurora A inhibitor, MLN8237, the pan-H3K9me-HMT inhibitor, chaetocin, is effective at reducing PDAC cell growth in vitro
Although MLN8237 has been actively tested for controlling PDAC growth with initial promising results (27, 28) , its efficacy remains to be improved. Thus, we searched for novel pathways to serve as additional targets that could potentially enhance the effects of MLN8237. The H3K9me mark is critical for maintaining the proper structure and function of centromeres (29) , which, if disrupted, causes several types of mitotic stress. We hypothesized that chaetocin, an inhibitor of all known H3K9me HMTs (30), would generate an added stress to mitotically arrested cells by MLN8237 and improve its beneficial effects. As an initial step toward defining the consequences of this combination, we first tested the effects of both drugs alone in PDAC cell lines. Fig. 1A shows that MLN8237 (200 nmol/L) reduced cell viability in 5 different human PDAC cells after 72 hours of treatment: BxPC-3 (76.0% AE 2.4% of control), Capan-2 (63.0% AE 4.6%), L3.6 (70.6% AE 1.6%), MIA PaCa-2 (78.9% AE 3.0%), and PANC-1 (89.5% AE 2.0%), as well as the mouse-derived PDAC line Pan02 (77.2% AE 4.5%). Similarly, treatment with the H3K9me HMT inhibitor, chaetocin, demonstrated a dose-dependent inhibition of cell growth in the same cell lines (Fig. 1B-G) . At 48 hours, the percentage of viability compared with no treatment control cells with 25, 50, 75, and 100 nmol/L chaetocin was 89.1% AE 5.0%, 65.6% AE 8.3%, 55.0% AE 9.2%, and 37.2% AE 5.7%, respectively, for BxPC-3 (of control); 88.3% AE 4.0%, 71.7% AE 3.5%, 60.0% AE 2.4%, and 58.2% AE 1.2%, for Capan-2; 118.5% AE 6.5%, 92.5% AE 4.0%, 91.1% AE 10.5%, and 47.2% AE 2.2%, for L3.6; 81.7% AE 5.5%, 59.2% AE 4.9%, 54.4% AE 3.6%, and 42.5% AE 2.6%, for MIA PaCa-2; 124.5% AE 6.1%, 114.1% AE 6.4%, 81.9% AE 6.7%, and 68.0% AE 4.2%, for PANC-1; and 99.1% AE 6.8%, 61.9% AE 4.3%, 49.1% AE 7.7%, and 27.3% AE 2.9%, for Pan02. Combined, these results demonstrate, for the first time, inhibition of PDAC cell growth in response to treatment with the pan-H3K9me HMT inhibitor, chaetocin, and also confirm that the AURKA inhibitor is similarly effective in this process. These baseline experiments guided the subsequent combination of these two inhibitors.
Chaetocin enhances the inhibitory effects of MLN8237 on PDAC cell growth in culture and in vivo
We combined MLN8237 and chaetocin at various concentrations to determine their combination index (CI), using CompuSyn software, which is based on the theory of Chou-Talalay Method to define additive effect (CI ¼ 1), synergism (CI < 1), or antagonism (CI > 1) in drug combinations (15) . We performed a 8 Â 8 matrix format using MTS assays, which investigated concentration ranges of 60-320 nmol/L of MLN8237 and 5-50 nmol/L of chaetocin on the same mouse (Pan02) and human (BxPC-3, Capan-2, L3.6, MIA PaCa-2, and PANC-1) PDAC cells tested with individual drugs. On the basis of initial concentrations ( Table S2 ). Subsequently, the drugs were combined at a fixed concentration ratio of chaetocin:MLN8237 at 1:2 based on their average IC 50 Fig. 2A) . In summary, the Fa-CI plots demonstrate that the MLN8237-chaetocin combination exhibited the highest synergy at high Fa values for the tested ratios. We performed clonogenic survival assays on L3.6, as one of the cell lines that displayed a strong synergistic effect with better CIs at higher Fa values (Fig. 2D ). Cells were exposed to concentration ranges of 22.5-90 nmol/L for MLN8237 and 7.5-30 nmol/L for chaetocin or a combination at a fixed ratio of chaetocin:MLN8237 at 1:3 for 7 days. MLN8237 alone did not substantially reduce surviving colonies, whereas the panH3K9me HMT inhibitor, chaetocin, induced a moderate reduction in clonogenic survival. However, as shown in Fig. 2H -I, in particular, the combination of MLN8237 at a concentration of 67.5 nmol/L and chaetocin at 22.5 nmol/L significantly reduced clonogenic survival with over 85% inhibition (86.1% AE 6.3%) (450 nmol/L, 900 nmol/L) and combination (150 nmol/L þ 450 nmol/L or 300 nmol/L þ 900 nmol/L, chaetocin þ MLN8237 respectively), Ela-Kras organoid viability was assessed by CellTiter-Glo 3D luminescent assay readings normalized to the vehicle-treated organoids. Each experiment was performed in triplicate, results expressed as mean AE SEM, and statistical analyses were performed using one-way ANOVA and multiple comparisons; ÃÃ , P 0.005; ÃÃÃ , P 0.0005. F, C57Bl/6 mice were orthotopically injected with syngeneic Pan02 cells constitutively expressing luciferase and allowed to recover and grow tumors for 1 week before initiating vehicle, chaetocin, or MLN9237 alone and combination treatments. To monitor in vivo tumor growth, mice were injected with D-luciferin at 0, 3, and 10 days of treatment and total flux (photons/second, p/s) measured for each mouse in the Xenogen IVIS-200 imaging system. Total flux was normalized to day 0 and averaged (mean AE SEM) across mice per condition and statistical significance was calculated by multiple t tests at each day using the Holm-Sidak correction for multiple comparisons.
Ã , P 0.05 for comparison of combination treatment to vehicle control. Treatments with individual drugs did not produce statistically significant effects. G, Representative images of mice injected with D-luciferin at day 10. compared with MLN8237 alone (28.4% AE 5.2%; 67.5 nmol/L) and 67.1% AE 5.2% inhibition with chaetocin alone (22.5 nmol/ L). The CI values at Fa75, 90, and 95 were 0.695, 0.510, and 0.421, respectively (Fig. 2J) . Similar experiments were performed with PANC-1 cells (Supplementary Fig. S1A-S1C) , which demonstrated CI values Fa75, 90, and 95 at 1.016, 0.944, and 0.912. Therefore, the combination of MLN8237 with chaetocin demonstrated synergy for reduction of clonogenic survival.
3D cultures more closely simulate in vivo conditions and often demonstrate increased resistance to drug treatments. Therefore, we repeated treatments on PDAC cell lines grown as spheroids, which are solid, 3D aggregates of cancer cells (17) . Formed spheroids were grown for 4 days before adding chaetocin, MLN8237, or their combination (Fig. 3A-C) . Similar to 2D cultures, the drug combination significantly reduced growth of PANC-1 spheroids than either drug alone as measured by acidic phosphatase (APH) assay ( Fig. 3A; 41.9% AE 2.4% reduction of growth with combination treatment versus 15.9% AE 1.6% with 900 nmol/L MLN8237 alone or 25.2% AE 1.5% with 300 nmol/L chaetocin alone). Images of the 3D spheroids confirm that the dense core of cells was reduced following combination treatment (yellow circles, Fig. 3C ). Performing a 5 Â 5 matrix dose curve, spheroids were exposed to concentration ranges of 150-1,800 nmol/L for MLN8237 and 50-600 nmol/L for chaetocin or a combination at a fixed concentration ratio of chaetocin: MLN8237 at 1:3. Thus, the combination is more effective than individual treatments ( Fig. 3B ; CI values of 0.307, 0.139, 0.0632, and 0.0369 for Fa50, 75, 90, and 95, respectively) for 3D cultures, which are increasingly favored for drug testing (17) .
We also evaluated these drugs in a more relevant 3D culture model (18) , namely organoids. Pancreatic ducts were isolated from Ela-Kras mice (19) and propagated in Matrigel to form organoid structures. Organoids derived from these murine models of PDAC can generate lesions that resemble pancreatic intraepithelial neoplasias (PanIN) and progress to invasive PDAC, thereby offering a useful tool for evaluating therapeutic approaches (18) . Organoids were treated with 150 or 300 nmol/L chaetocin, 450 or 900 nmol/L MLN8237, or their combination (150 þ 450nmol/L; 300 þ 900 nmol/L) for 72 hours, and viability of cells was evaluated by CellTiter-Glo assay ( Fig. 3D and E). With 150 nmol/L chaetocin and 450 nmol/L MLN8237, the combination showed a significant reduction in viability (50.5% AE 3.0% compared with vehicle) in contrast to MLN8237 (19.8% AE 3.4% reduction compared with vehicle) and chaetocin alone (30.6% AE 2.9% reduction compared with vehicle; Fig. 3E ). Similarly, 300 nmol/L chaetocin and 900 nmol/L MLN8237 significantly reduced viability (69.2% AE 3.5% compared with vehicle) in comparison with MLN8237 (16.3% AE 3.3% reduction compared with vehicle) and chaetocin alone (54.3% AE 4.4% reduction compared with vehicle; Fig. 3E ). Representative images of the organoids demonstrate appreciable reduction in size and disruption of the 3D structure in the combination treatment (Fig. 3D) .
Finally, we evaluated the effect of the AURKA and panH3K9me HMT inhibitors using orthotopic xenografts. Pan02 cells stably expressing luciferase were injected into the pancreas of C57BL/6 mice. These cells allow accurate monitoring of timedependent in vivo growth of xenografts. Xenografts were treated with vehicle control, chaetocin alone, MLN8237 alone, or their combination (n ¼ 5/group) and monitored by bioluminescence. Mean bioluminescence values are shown at 0, 3, and 10 days of treatment (Fig. 3F) . While individual treatments did not result in a statistically significant reduction in tumor growth (normalized total flux compared with start of treatment 1.04 AE 0.21 p/s for control animals versus 0.41 AE 0.17 p/s for chaetocin alone, P > 0.05; or 0.57 AE 0.19 p/s for MLN8237 alone, P > 0.05), the group receiving the combination displayed significant reduction of tumor growth (0.25 AE 0.08 p/s, P < 0.05) after 10 days of treatment (representative images, Fig. 3G) . Therefore, the MLN8237-chaetocin combination is more effective than each of the drugs alone for inhibiting cell growth both, in vitro and in vivo.
The MLN8237-chaetocin combination inhibits PDAC growth via a cellular mechanism involving mitotic catastrophe
As the AURKA and HP1-HMT pathways are both involved in the regulation of cell division, we examined the mechanisms by which antagonizing these pathways leads to PDAC cell growth inhibition. Using fluorescence-based measurement of live-cell protease activity and luminogenic-based substrate to detect caspase-3/7 activation, we confirmed reduction of cell viability along with a corresponding increase of apoptotic indicators in PANC-1 cells treated with vehicle, 30 nmol/L chaetocin, 90 nmol/L MLN8237, or their combination. After 72 hours, relative cell viability (Fig. 4A ) of combination-treated Ã , P 0.05; ÃÃÃ , P 0.0005. C, FACS analysis of PANC-1 cells treated for 48 hours with chaetocin, MLN8237, and combination treatments resulted in slightly increased G 2 -M arrest for single treatments and nearly complete G 2 -M arrest and cell death (sub-G 1 events shown in light green) for the combination treatment. Representative FACS cell-cycle graphs illustrate the significant shift and average percentage (n ¼ 2) of events in each phase of cell cycle, G 1 , S, or G 2 -M are graphed with relative percentages indicated in each segment (D). E, L3.6 cells were treated with vehicle, chaetocin, MLN8237, or combination for 48 hours, fixed, and stained antibodies to g-tubulin (green), a-tubulin (red), and DNA stained with DAPI (blue) to consider mitotic progression. Over 150 mitotic cells were observed and quantified as normal, aberration, or catastrophe and resultant graph indicates the percentage of the total number of cells counted. F, Representative images of cells counted as normal mitosis (vehicle), multiple spindle poles (chaetocin and MLN8237 alone), and total disruption of the spindle apparatus in mitotic catastrophe during combination treatment. Scale bar, 2,000 nm. G, Electron microscopy images of PANC-1 cells after 72 hours of treatment demonstrated multinucleated cells (black arrows). Normal mitoses are indicated by ( Ã ). Evidence of mitotic cell death/mitotic catastrophe is shown in the combination treatment (red arrow). Scale bar, 10 mm. H, PANC-1 lysates after 48 hours of treatment indicate that the relative levels of P-S10 H3 and P-S139 H2A.X (indicators of mitotic catastrophe) are increased in the combination treatment by Western blot analysis, with H2B as loading control. Pancreatic tissue from orthotopic xenografts was stained by IHC for P-S139 H2A.X as a measure of mitotic catastrophe in vivo. I, Quantification of average positive staining cells per field are graphed AE SEM with 5 field views per sample. Statistical significance was performed using a Student t test to compare combination treatment to all other conditions, ÃÃÃ , P 0.0005. J, Representative fields illustrate the increased number of positively stained cells (black arrows) in the combination-treated animals as compared with vehicle, chaetocin, or MLN8237 alone. Scale bar, 0.1 mm. Fig. S1D and S1E ). Subsequently, we measured how these inhibitors impact the cell cycle using fluorescenceactivated cell sorting (FACS). We found that while chaetocin and MLN8237 alone caused modest accumulation of cells with G 2 -M DNA content (35.6% AE 0.04% and 22.0% AE 3.3%, respectively, versus 17.6% AE 0.03% in vehicle control-treated cells), their combination induced a substantial shift of the cells to G 2 -M (67.2% AE 1.4%) with an increase in sub-G 1 population ( Fig. 4C and D) . Interestingly, confocal and electron microscopy demonstrated that the effect of the combination was due to chromosomal instability, mitotic aberrations, and ultimately induction of mitotic cell death (Fig. 4E-G) . For instance, immunofluorescence with anti-a-tubulin for spindle poles and anti-g-tubulin for centrosomes showed that cells treated with either drug exhibited mitotic aberrations, including multipolar spindles, centrosome disruption or lagging, unorganized chromosomes ( Fig. 4E and F ). While cells with vehicle treatment displayed mitotic abnormalities in only 15.9% of the mitotic population (n ¼ 208), 31.6% of chaetocin-treated (n ¼ 171), and 42.6% of MLN8237-treated (n ¼ 169) cells in mitosis had these types of aberrations. Cells with complete disruption of the mitotic spindle and chromosome alignment were categorized as undergoing mitotic catastrophe. None of the vehicle-treated cells exhibited this level of mitotic disturbance. However, 9.4% of chaetocin-treated cells and 33.1% of MLN8237-treated cells showed mitotic catastrophe. Interestingly, the combination of chaetocin and MLN8237 demonstrated a significant portion of cells in mitotic catastrophe rather than mitotic aberrations (81.8% mitotic catastrophe versus 11.8% mitotic aberrations; n ¼ 187; Fig. 4E) . Similarly, PANC-1 cells treated by the combination show increased mitotic catastrophe (29.9% mitotic catastrophe, n ¼ 147, Supplementary Fig. S1F ). Scanning electron microscopy confirmed that while chaetocin and MLN8237 individually caused multinucleated cells (Fig. 4G, black arrows) , their combination resulted in multiple nuclei per cell and a significant proportion of cells that had died in mitosis, as evidenced by a highly disorganized cytoplasm, altered vesicular organelles, and presence of electron dense condensed chromosomes (Fig. 4G,  red arrow) . Biochemically, the combined treatment with MLN8237 and chaetocin resulted in increased levels of P-S10-H3 and P-S139-H2A.X, as measured by Western blot analysis (Fig. 4H) . The coinciding increase of both histone marks is characteristic of mitotic catastrophe (31), further confirming this phenomenon. Notably, we also checked tissue from our treatment of orthotopic xenografts for P-S139-H2A.X-positive cells by IHC to confirm this observation in vivo. Congruently, we found that orthotopic xenografts from mice receiving the combination displayed a higher number of P-S139-H2A.Xpositive cells ( Fig. 4I and J 0.0002), or MLN8237 alone (1.4 AE 0.24 positive cells/field; P < 0.0001), confirming that the combination had the expected effect in vivo. Collectively, our data demonstrate that the cellular mechanism underlying PDAC growth inhibition observed with combined MLN8237 and chaetocin treatment is through induction of mitotic catastrophe. Thus, these results prompted the search for molecular mechanisms to explain this effect by focusing on how these drugs modify the transcriptional response by RNA-sequencing (RNA-seq), as well as cellcycle checkpoint pathways that are activated by chromosomal instability.
RNA-seq defines molecular markers of the MLN8237-chaetocin response
We utilized RNA-Seq to define molecular markers for the effect of the MLN8237-chaetocin combination. PDAC cells were treated with individual drugs or their combination and compared with vehicle. Treatment was limited to 24 hours to extract RNA before significant mitotic catastrophe occurred to capture the transcriptional effect. Figure 5A shows the heatmap from triplicate experiments. Supplementary Table S3 lists the specific values for expression of differentially expressed genes (DEG) found in response to treatment. A Venn diagram (Fig. 5B ) compared the DEG in chaetocin alone and the combination treatment. Here, 548 genes are indicated as changed specifically as the result of the combination and not found to be changing in the chaetocin alone treatment. Furthermore, MLN8237 alone did not result in any significant DEG at the dose used for all experiments, with the exception of two pseudogenes. Notably, the majority (83%) of the 548 DEG in response to the combination were upregulated, consistent with inhibition of the repressive H3K9me pathway, which represents one arm of the treatment and is expected to derepress gene expression. A bar graph with genes grouped by ontological function and number of DEG activated or repressed by combination treatment, colored red and green, respectively, is shown in Fig. 5C . We also found that the treatment regulates genes, which promoters contain xenobiotic response elements involved in drug metabolism, including CYP1A1, CYP1B1, CYP2B7P, CYP7B1, CYP4F12, CYP2E1, and CYP2C8, serving as an internal positive control for drug exposure. Interestingly, 36% (199/548) of DEG are noncoding RNAs, constituting an overrepresentation beyond the expected number. Among these transcripts, 77% of them belong to the group of the recently reported noncoding regulatory RNAs, known as mCARs, which appear to be critical structural components of chromosomes (32) . In the similar functional category, the entire histone 1 cluster (HIST1H4I, HIST1H4H, HIST1H4E, HIST1H3J,  HIST1H3D, HIST1H3C, HIST1H2BO, HIST1H2BN, HIST1H2BJ , HIST1H2BG, HIST1H2AM, HIST1H2AG, and HIST1H2AD) was also represented. The percentage of DEG associated to chromosome structure in response to the drug combination was higher than expected for a nonspecific effect and may likely reflect a cellular response to alterations in these organelles, which are observed during mitotic catastrophe. In addition to chromosomal markers, the remaining DEGs participate in chromatin organization, transcription, and epigenetics, cell adhesion and extracellular matrix, cell signaling, cytoskeleton, metabolism, mitochondria homeostasis, membrane proteins, cytoskeleton, channels and transporters, as well as cell cycle, senescence, and apoptosis (Fig.  5C ). Whether the changes in gene expression result from effects of abnormal gene regulation in response to the drugs or reflect a role in mitotic catastrophe is less clear. Nevertheless, these experiments provide a number of potential markers, which can serve to monitor the effectiveness of this combination.
Mitotic catastrophe induced by combined MLN8237-chaetocin treatment is characterized by aberrant mitotic checkpoint signaling and decreased centromeric H3K9 methylation
To unravel molecular mechanisms that may explain how synergism of the MLN8237-chaetocin combination triggers mitotic death, we investigated the integrity of G 2 -M checkpoint pathways. ATM (ataxia telangiectasia mutated) and ATR (ATM and Rad3-related) are part of a unique family of serine-threonine kinases functioning as transducers of DNA signals (33) . We hypothesized that, in the combination treatment, these pathways may be affected due to the observed centromere changes, mitotic instability, prolonged cell-cycle arrest, and ultimately, mitotic catastrophe. Testing this hypothesis followed the rationale that these kinases orchestrate a network of cellular processes that maintains genomic integrity by signaling to downstream kinases, such as Chk1. Chk1 functions in survival and cell-cycle checkpoints, in particular cell-cycle arrest before mitosis in response to DNA damage (34) . Activated Chk1 phosphorylates the dual specificity phosphatase Cdc25C on Ser216, which sequesters this phosphatase in a complex within the cytoplasm, thereby preventing Cdc25C from activating Cdk1 through removal of the inhibitory phosphorylation. As a result, the Cdk1/Cdc2-cyclin B complex is maintained in an inactive state to block entry into mitosis. In MLN8237-treated cells, ATM and ATR along with P-S345 Chk1 were present, presumably leading to high levels of P-S216 Cdc25c, its inactive form (Fig. 6A) . Cdk1 was also inactive, as reflected by high levels of P-Y15 Cdk1/cdc2. High levels of Wee1, which phosphorylates Y15-Cdk1/cdc2 leading to its inactivation, likely, reinforced this effect (Fig. 6A) . Therefore, treatment with MLN8237 leads to signals that are known to render the Cdk1-Cyclin B complex unable to mediate cell division, accompanied by G 2 -M arrest ( Fig. 6B; ref. 31 ). Chaetocin treatment alone had ATM and ATR levels similar to control and MLN8237-treated cells (Fig. 6A ). There were slight decreases in the amounts of P-S345 Chk1 and P-S216 Cdc25c in comparison with control and MLN8237, although not to the extent observed in the combination. However, the slight decrease in inactive P-S216 Cdc25c did not result in the presence of active P-T48 Cdc25c (Fig. 6A) . The presence of inactive P-Y15 Cdk1/cdc2 remained, while a low level of active P-T161 Cdk1/cdc2 was also detected. Levels of cyclin B stayed constant. Overall, the molecular response to chaetocin alone was not markedly distinct from control-treated cells in key mitotic checkpoints. However, chaetocin with MLN8237 triggered an aborted response to bypass this G 2 -M arrest, which ultimately resulted in mitotic catastrophe and death. At the molecular level, lysates from the MLN8237-chaetocin combination demonstrated Chk1 inactivation by decreased levels of both, total and phosphorylated form of this protein (Fig. 6A) . Chk1 inactivation was also evidenced by a decrease in P-S216 Cdc25c (inactive) with a corresponding increase in P-T48 Cdc25c (active). This Cdc25c activation led to Cdk1/cdc2 dephosphorylation (Y15), allowing activation of the Cdk1/cdc2-Cyclin B complex, as observed by increased P-T161 Cdk1/cdc2 (Fig. 6A) . Concordantly, low levels of Wee1 likely strengthened this effect along with increased Cyclin B (Fig. 6A) . Central to these G 2 -M arrest pathways is p53 (35) , which levels were significantly ablated by the combination (Fig. 6A) , a phenomenon that has been implicated in mitotic catastrophe (36, 37) . Notably, p53 downregulation occurs at the protein level without changes at the transcript level (Supplementary Table S4 ) in real-time PCR, which yielded a fold change for p53: chaetocin, 1.130; MLN8237, 1.039; combination, À1.219 each compared with vehicle, or in RNA-seq (log fold change: chaetocin, À0.169; MLN8237, À0.156; combination, À0.415 each compared with vehicle). Similarly, none of the other mitotic checkpoint proteins were altered at the transcript level (Supplementary Table S4 ), indicating that these changes are posttranscriptional events. As a consequence, combination treatment results in a signal for inducing mitotic progression (Fig. 6B ), but as both the AURKA and H3K9me pathways are inhibited, this response appears to abort with cells ultimately entering mitotic catastrophe and cell death due to the structural disorder and chromosomal instability (Fig. 4C-G) . As chaetocin is an inhibitor of all known H3K9me HMTs, we checked the levels of the dimethyl (H3K9me2) and trimethyl (H3K9me3) posttranslational marks of K9H3. As expected, levels of both, H3K9me2 and H3K9me3 decreased with chaetocin alone, as observed by Western blot analysis (Fig. 6C) . Interestingly, levels of H3K9me2 were also reduced with MLN8237, and both of these posttranslational modifications were reduced even more in the combination compared with either of the individual drugs (Fig. 6C) . In mitotic cells, the H3K9me3 mark colocalizes with pericentromeric heterochromatin (29) . Using immunofluorescence, we observed a decrease in pericentromeric H3K9me3 in mitotic cells treated with chaetocin or MLN8237 alone compared with control, which was almost completely absent in cells treated with their combination (Fig. 6D; Supplementary Fig. S1G ), congruent with our Western blot findings. In summary, the molecular signature in the combination treatment reflects one of cell-cycle progression combined with signals indicative of mitotic catastrophe, namely the concurring increase of both P-S10-H3 and P-S139-H2A.X histone marks (Fig. 4H) , and decreased centromeric H3K9 methylation (Fig. 6D) , suggesting that mitotic cell death results from aberrant checkpoint signaling along with severe chromatin-DNA damage.
Discussion
Epigenomic-based pharmacology has the potential to serve as a robust tool to improve the future treatment of PDAC. The results of the current study significantly contribute to the field of experimental therapeutics by demonstrating how to inhibit PDAC growth through combined targeting of an oncogene and epigenetic regulator (genetic-to-epigenetic crosstalk). We tested the efficiency of this approach by jointly targeting AURKA and one of its epigenetic targets, the H3K9me pathway. We also dissected cellular and molecular mechanisms by which this combination leads to a cytotoxic effect. Thus, it is important to consider how our evidence supports a model by which these types of therapies may work and how similar approaches can be translated to other genetic-to-epigenetic pathways controlling cancer growth.
Antitumor agents have the possible cellular outcomes of cytotoxicity by cell death or cytostasis through cell-cycle arrest and/or senescence (38) . While senescent cells have the benefit of suppressing tumorigenesis, unfortunately, they leave cells metabolically active that can potentially contribute to progression and therapy resistance. MLN8237 (alisertib), a MLN8054 derivative, works as highly specific ATP-competitive drug that binds AURKA and inhibits T288 phosphorylation (39) . As a result of AURKA inhibition, MLN8237 blocks G 2 -M cell-cycle progression, induces polyploidy, and results in senescence (40) . As AURKA is overexpressed in many cancers, including PDAC, it continues to be a feasible target for therapy. While several AURKA inhibitors have been developed, MLN8237 remains the most promising due to minor to moderate side effects. There are numerous ongoing phase I and II trials with MLN8237 as a single agent or in combination with other drugs in advanced solid and hematologic malignancies (41) . Combination of MLN8237 with cytotoxic drugs, including taxanes, cisplatin, vincristine, and gemcitabine among others, potentiates anticancer activity. However, even though phase I and II studies have offered encouraging results, the first phase III study with MLN8237 was discontinued due to unsatisfactory efficacy, leaving some yet unanswered questions for MLN8237 use in clinical settings. Therefore, although MLN8237 holds promise as a therapeutic agent, there remains much speculation that this drug will ultimately better serve in combination with other agents if it is to gain clinical approval. In particular, the optimal endpoint of such therapy, rather than senescence, would be to effectively eliminate malignant cells through cell death.
Our data demonstrate that the combined inhibition of AURKA, and the H3K9me pathway is synergistic (Figs. 2 and 3 ). An enhanced effect of the combination to inhibit PDAC growth is also observed with 3D spheroid and organoid cultures, as well as xenografts in vivo (Fig. 3) . This is consistent with the fact that these targets are in the same biological pathway that aids to the proper completion of mitosis (12) . Upon cell-cycle arrest caused by AURKA inhibition, the mitotic machinery is exposed longer to targeting by the H3K9me pathway, which during mitosis regulates centromere structure. Histones associated with centromeric heterochromatin are typically hypoacetylated (42) and methylated on H3K9 (29) . H3K9me levels rapidly increase upon mitotic entry, reaching maximum in metaphase (13) . Congruent with previous reports (13) , disruption of this H3K9me-mediated centromeric pathway in mitosis ( Fig. 6C and D; Supplementary Fig.  S1G) , which in the current study is achieved through the combined use of a pan-H3K9me HMT and an AURKA inhibitor, leads to mitotic aberrations ( Fig. 4E and F; Supplementary Fig. S1F ), abnormal mitotic checkpoint responses (Fig. 6A-B) , and cell death by mitotic catastrophe. Furthermore, the cellular response to the drug combination is marked by expression changes of genes involved in drug metabolism, mCARs, as well as genes associated to chromosome structure, as observed by RNA-seq (Fig. 5) . Thus, inhibition of the H3K9me epigenetic pathway, specifically in mitosis, offers a unique therapeutic approach not characteristically considered when utilizing epigenetic agents, which have more commonly been tested for modulating gene expression during interphase.
Mitotic catastrophe is an oncosuppressive mechanism defined as a mode of cell death resulting from aberrant mitosis (43) . Several drugs, including spindle assembly inhibitors, DNA-damaging agents, and radiation, induce mitotic catastrophe. Microtubule-hyperpolymerizing agents, such as paclitaxel and docetaxel, and depolymerizing agents of the Vinca-alkaloid type (vinblastine, vincristine, and vindesine) are mitotic inhibitors that influence microtubule dynamics by binding to tubulin dimers, leading to spindle disturbances (44) . There are other inducers of mitotic catastrophe that are undergoing evaluation in preclinical and clinical settings, including inhibitors of checkpoint kinases (CHK), polo-like kinases (PLK), PARP, and survivin. Mitotic catastrophe ensues from a combination of dysfunctional cell-cycle checkpoints, particularly those related to DNA structure and spindle assembly, along with cellular damage (45) . Here, we find that the combination of AURKA and H3K9me-HMT inhibition elicits an aberrant response of checkpoint proteins, bypassing the Chk1-Cdc25c-Cdk1-dependent G 2 -M arrest observed with MLN8237 alone (Fig. 6A and B) , in the presence of DNA damage marked by high P-S139-H2A.X levels (Fig. 4H-J) to culminate in mitotic catastrophe. The phenomenon of mitotic catastrophe is a desirable outcome in cancer therapy, and thus, the current study, which achieves this effect by targeting a genetic-to-epigenetic pathway, provides a model for effective combinatorial therapeutic approaches for PDAC, and likely other cancers.
In lieu of these findings, it is tempting to speculate how inhibition of other genetic-to-epigenetic pathways may exert similar effects. For instance, another well-known repressive methyl-histone mark, H3K27Me, mediated by the Polycomb complex, is also retained through mitosis and required for proper cell-cycle progression (46, 47) . Similarly, the H4K20me1 demethylase, PHF8, influences G 2 -M transition and its loss leads to highly defective mitosis (48) . Brd4, a member of the BET bromodomain family that has elicited significant attention as cancer targets, localizes to chromosomes during mitosis and plays an essential role in mitotic spindle assembly (49) . Interestingly, a recent study found that the combination of the BET bromodomain inhibitor JQ1 and vincristine, an anti-microtubule drug that arrests cells at mitosis, synergistically induces the formation of aberrant mitotic spindles, cell cycle arrest at G 2 -M and death in neuroblastoma cells (50) . Thus, inhibition of various epigenetic pathways has the possibility to be exploited for the efficient development of therapeutic modalities in the future.
In summary, the current study advances our understanding of how epigenetic inhibitors can be utilized in novel therapeutic approaches. Our results outline a model for combined targeting of a genetic-to-epigenetic pathway to inhibit PDAC cell growth via a cytotoxic mechanism that involves perturbation of normal mitotic progression to end in mitotic catastrophe, an attractive outcome in oncology. Furthermore, it suggests an important and provocative consideration for harnessing the capacity of cell-cycle inhibitors in efforts to enhance the future use of epigenetic inhibitors.
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